08:00 , Dec 4, 2006 |  BioCentury  |  Strategy

Crucell chronicles

Crucell chronicles Weekly stock price for Crucell (Euronext:CRXL; CRXL) on Euronext Amsterdam tracked against selected events since 2000. 6/30/00 - IntroGene and U-BiSys merge and change name to CrucellA. 10/27/00 - Raises E144M ($119M) in...
08:00 , Dec 4, 2006 |  BioCentury  |  Strategy

PER.C6 perseverance

While most of Europe's bellwether biotechs are spinouts from big pharma, Crucell N.V. is showing that there are other ways that European companies can build critical mass. Since its formation in 1993 as gene therapy...
08:00 , Jan 27, 2003 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Crucell N .V. (Euronext:CRXL; CRXL), Leiden, the Netherlands Business: Cancer, Autoimmune/Inflammation, Infectious diseases ING analyst Sally Bennett lowered her rating to "hold" from "buy" to reflect her concerns about CRXL's antibody generation business. Last month,...
08:00 , Jan 6, 2003 |  BioCentury  |  Finance

Ebb & Flow

Swiss venture capital firms HBM BioVentures and NMT New Medical Technologies are joining forces to create a firm with about CHF830 million ($640 million) under management. The merged firms, which both invest heavily in biotech...
08:00 , Dec 24, 2002 |  BC Extra  |  Top Story

Centocor returns antibody to Crucell

Centocor (Malvern, Penn.) returned to Crucell (Euronext:CRXL; CRXL) all rights to the CD46 target and anti-CD46 antibody, which it had licensed in 2001. Centocor , a Johnson & Johnson (JNJ) subsidiary, and CRXL said they...